首页 > 最新文献

Journal of Clinical Apheresis最新文献

英文 中文
A retrospective study to investigate the efficacy and safety of granulocyte and monocyte adsorptive apheresis in patients with primary sclerosing cholangitis with ulcerative colitis 回顾性研究粒细胞和单核细胞吸附分离治疗原发性硬化性胆管炎合并溃疡性结肠炎的疗效和安全性。
IF 1.5 4区 医学 Q4 HEMATOLOGY Pub Date : 2023-11-21 DOI: 10.1002/jca.22099
Ayumi Ito, Shun Murasugi, Maria Yonezawa, Teppei Omori, Shinichi Nakamura, Katsutoshi Tokushige

Background and Aims

Primary sclerosing cholangitis has a poor prognosis and can be accompanied by ulcerative colitis. Infection control is essential, so immunosuppressive drugs should ideally be preferably. Granulocyte and monocyte adsorptive apheresis does not suppress the immune system and is used to treat ulcerative colitis. Therefore, this study investigated the efficacy and safety of granulocyte and monocyte adsorptive apheresis in patients with primary sclerosing cholangitis and ulcerative colitis.

Methods

We retrospectively evaluated data from patients with primary sclerosing cholangitis with ulcerative colitis who visited our hospital from April 2000 to December 2022 and underwent granulocyte and monocyte adsorptive apheresis (n = 10, number of treatment cycles = 15). Study endpoints were remission induction rate and safety, assessed as changes in liver functions and adverse events.

Results

Seven of the 10 patients were male. The median (min-max) age was 23 (18-77) years. The most common disease type was right-dominant pancolitis. Remission occurred after 86.6% of cycles (13/15). Serum alkaline phosphatase and Aspartate transaminase were significantly lower after treatment (P = .0124, P = .002), and no negative effects on liver function were seen. The only adverse events were headache (n = 1) and decreased blood pressure (n = 1).

Conclusions

Granulocyte and monocyte adsorptive apheresis has high efficacy for intestinal lesions and improves alkaline phosphatase and aspartate transaminase levels (high levels are a poor prognosis factor). It appears to be a treatment option in patients with primary sclerosing cholangitis associated with ulcerative colitis.

背景与目的:原发性硬化性胆管炎预后差,可合并溃疡性结肠炎。感染控制是至关重要的,因此免疫抑制药物应该是理想的。粒细胞和单核细胞吸附分离不抑制免疫系统,用于治疗溃疡性结肠炎。因此,本研究探讨了粒细胞和单核细胞吸附采珠术治疗原发性硬化性胆管炎和溃疡性结肠炎的疗效和安全性。方法:回顾性分析2000年4月至2022年12月在我院接受粒细胞和单核细胞吸附采珠术治疗的原发性硬化性胆管炎合并溃疡性结肠炎患者的资料(n = 10,治疗周期数= 15)。研究终点是缓解诱导率和安全性,以肝功能的变化和不良事件来评估。结果:10例患者中男性7例。中位(最小-最大)年龄为23岁(18-77岁)。最常见的疾病类型为右显性全结肠炎。86.6%(13/15)的周期后出现缓解。治疗后血清碱性磷酸酶和天冬氨酸转氨酶显著降低(P =。0124, P = .002),肝功能未见不良影响。唯一的不良事件是头痛(n = 1)和血压下降(n = 1)。结论:粒细胞和单核细胞吸附采珠术治疗肠道病变疗效高,可提高碱性磷酸酶和天冬氨酸转氨酶水平(高水平为预后不良因素)。它似乎是原发性硬化性胆管炎合并溃疡性结肠炎患者的一种治疗选择。
{"title":"A retrospective study to investigate the efficacy and safety of granulocyte and monocyte adsorptive apheresis in patients with primary sclerosing cholangitis with ulcerative colitis","authors":"Ayumi Ito,&nbsp;Shun Murasugi,&nbsp;Maria Yonezawa,&nbsp;Teppei Omori,&nbsp;Shinichi Nakamura,&nbsp;Katsutoshi Tokushige","doi":"10.1002/jca.22099","DOIUrl":"10.1002/jca.22099","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Primary sclerosing cholangitis has a poor prognosis and can be accompanied by ulcerative colitis. Infection control is essential, so immunosuppressive drugs should ideally be preferably. Granulocyte and monocyte adsorptive apheresis does not suppress the immune system and is used to treat ulcerative colitis. Therefore, this study investigated the efficacy and safety of granulocyte and monocyte adsorptive apheresis in patients with primary sclerosing cholangitis and ulcerative colitis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively evaluated data from patients with primary sclerosing cholangitis with ulcerative colitis who visited our hospital from April 2000 to December 2022 and underwent granulocyte and monocyte adsorptive apheresis (n = 10, number of treatment cycles = 15). Study endpoints were remission induction rate and safety, assessed as changes in liver functions and adverse events.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Seven of the 10 patients were male. The median (min-max) age was 23 (18-77) years. The most common disease type was right-dominant pancolitis. Remission occurred after 86.6% of cycles (13/15). Serum alkaline phosphatase and Aspartate transaminase were significantly lower after treatment (<i>P</i> = .0124, <i>P</i> = .002), and no negative effects on liver function were seen. The only adverse events were headache (n = 1) and decreased blood pressure (n = 1).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Granulocyte and monocyte adsorptive apheresis has high efficacy for intestinal lesions and improves alkaline phosphatase and aspartate transaminase levels (high levels are a poor prognosis factor). It appears to be a treatment option in patients with primary sclerosing cholangitis associated with ulcerative colitis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"39 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138291080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fractionated plasma separation and adsorption integrated with continuous veno-venous hemofiltration in patients with acute liver failure: A single center experience from China 急性肝功能衰竭患者血浆分离和吸附结合持续静脉-静脉血液滤过:中国单中心经验
IF 1.5 4区 医学 Q4 HEMATOLOGY Pub Date : 2023-11-20 DOI: 10.1002/jca.22100
Jianhua Dong, Li Huang, Chuan Li, Bian Wu, Xi Yang, Yongchun Ge

Objective

To evaluate the clinical efficacy and safety of fractionated plasma separation and adsorption integrated with continuous veno-venous hemofiltration (FPSA-CVVH) treatment in patients with acute liver failure (ALF).

Methods

In this retrospective study, we enrolled patients with ALF (serum total bilirubin >10 mg/dL or Model for End-Stage Liver Disease [MELD] Score >18) hospitalized between August 2017 and August 2022. All patients had at least two sessions of FPSA-CVVH. The primary measure of treatment efficacy was the reduction ratios (RRs) of bilirubin after each session of FPSA-CVVH.

Results

Seventy-eight patients with ALF were enrolled. The MELD score at baseline was 22.9 ± 7.5. The mean total bilirubin was 22.05 ± 5.94 mg/dL, direct bilirubin was 16.33 ± 4.60 mg/dL and indirect bilirubin was 3.43 ± 1.60 mg/dL. One hundred and eighty seven sessions of FPSA-CVVH treatment lasting 8 hours each were performed. After a single session, serum total bilirubin, direct bilirubin and indirect bilirubin were significantly decreased. RRs were 52.0% ± 7.6% for total bilirubin, 59.4% ± 13.0% for direct bilirubin and 36.9% ± 15.4% for indirect bilirubin. Twenty nine patients (37.2%) survived and were discharged from the hospital, 12 of them recovered their liver function while the remaining 17 patients needed intermittent artificial liver support therapy.

Conclusion

FPSA-CVVH therapy is an effective artificial liver support therapy in patients with ALF. It may be considered as a “bridge technique” to the recovery of liver function in critical ill patients with ALF.

目的:评价血浆分离吸附联合连续静脉-静脉血液滤过(FPSA-CVVH)治疗急性肝衰竭(ALF)的临床疗效和安全性。方法:在这项回顾性研究中,我们招募了2017年8月至2022年8月住院的ALF(血清总胆红素>10 mg/dL或终末期肝病模型[MELD]评分>18)患者。所有患者至少有两次FPSA-CVVH。治疗效果的主要衡量指标是每次FPSA-CVVH治疗后胆红素的降低率(rr)。结果:78例ALF患者入组。基线MELD评分为22.9±7.5。平均总胆红素为22.05±5.94 mg/dL,直接胆红素为16.33±4.60 mg/dL,间接胆红素为3.43±1.60 mg/dL。进行了187次FPSA-CVVH治疗,每次持续8小时。单次治疗后,血清总胆红素、直接胆红素和间接胆红素均显著降低。总胆红素的rr为52.0%±7.6%,直接胆红素为59.4%±13.0%,间接胆红素为36.9%±15.4%。29例(37.2%)患者存活出院,其中12例肝功能恢复,其余17例需间歇人工肝支持治疗。结论:FPSA-CVVH治疗是ALF患者有效的人工肝支持治疗方法。它可以被认为是ALF危重患者肝功能恢复的“桥梁技术”。
{"title":"Fractionated plasma separation and adsorption integrated with continuous veno-venous hemofiltration in patients with acute liver failure: A single center experience from China","authors":"Jianhua Dong,&nbsp;Li Huang,&nbsp;Chuan Li,&nbsp;Bian Wu,&nbsp;Xi Yang,&nbsp;Yongchun Ge","doi":"10.1002/jca.22100","DOIUrl":"10.1002/jca.22100","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To evaluate the clinical efficacy and safety of fractionated plasma separation and adsorption integrated with continuous veno-venous hemofiltration (FPSA-CVVH) treatment in patients with acute liver failure (ALF).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this retrospective study, we enrolled patients with ALF (serum total bilirubin &gt;10 mg/dL or Model for End-Stage Liver Disease [MELD] Score &gt;18) hospitalized between August 2017 and August 2022. All patients had at least two sessions of FPSA-CVVH. The primary measure of treatment efficacy was the reduction ratios (RRs) of bilirubin after each session of FPSA-CVVH.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Seventy-eight patients with ALF were enrolled. The MELD score at baseline was 22.9 ± 7.5. The mean total bilirubin was 22.05 ± 5.94 mg/dL, direct bilirubin was 16.33 ± 4.60 mg/dL and indirect bilirubin was 3.43 ± 1.60 mg/dL. One hundred and eighty seven sessions of FPSA-CVVH treatment lasting 8 hours each were performed. After a single session, serum total bilirubin, direct bilirubin and indirect bilirubin were significantly decreased. RRs were 52.0% ± 7.6% for total bilirubin, 59.4% ± 13.0% for direct bilirubin and 36.9% ± 15.4% for indirect bilirubin. Twenty nine patients (37.2%) survived and were discharged from the hospital, 12 of them recovered their liver function while the remaining 17 patients needed intermittent artificial liver support therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>FPSA-CVVH therapy is an effective artificial liver support therapy in patients with ALF. It may be considered as a “bridge technique” to the recovery of liver function in critical ill patients with ALF.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"39 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138176247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Crude collection efficiency of CD34+ hematopoietic stem cell apheresis CD34+造血干细胞单采的粗集效率。
IF 1.5 4区 医学 Q4 HEMATOLOGY Pub Date : 2023-11-08 DOI: 10.1002/jca.22096
Yandy Marx Castillo-Aleman MD

Understanding the apheresis principles for harvesting hematopoietic stem cells (HSCs) is critical for performing efficient procedures. However, despite significant advances in estimating the collection efficiency (CE) of aphereses, many confounding factors still need to be addressed in the classical calculations. The CE values are unrestricted, and many procedures exhibit CEs of a given cell population greater than 100%. This report introduces a simple equation that estimates the “crude” CE, which ranges from 0% to 100% and intrinsically considers the contribution of donor-related variables such as the pre-procedure mobilization and intra-apheresis recruitment of CD34+ cells (as a convenient marker for HSCs), as well as the performance of the apheresis system itself.

了解采集造血干细胞(HSC)的单采原理对于执行有效的程序至关重要。然而,尽管在估计单采采集效率(CE)方面取得了重大进展,但在经典计算中仍需要解决许多混杂因素。CE值是不受限制的,并且许多程序显示给定细胞群体的CE大于100%。本报告介绍了一个简单的方程,用于估计“粗略”CE,其范围从0%到100%,并从本质上考虑了供体相关变量的贡献,如CD34+细胞的术前动员和单采内募集(作为HSC的方便标记),以及单采系统本身的性能。
{"title":"Crude collection efficiency of CD34+ hematopoietic stem cell apheresis","authors":"Yandy Marx Castillo-Aleman MD","doi":"10.1002/jca.22096","DOIUrl":"10.1002/jca.22096","url":null,"abstract":"<p>Understanding the apheresis principles for harvesting hematopoietic stem cells (HSCs) is critical for performing efficient procedures. However, despite significant advances in estimating the collection efficiency (CE) of aphereses, many confounding factors still need to be addressed in the classical calculations. The CE values are unrestricted, and many procedures exhibit CEs of a given cell population greater than 100%. This report introduces a simple equation that estimates the “crude” CE, which ranges from 0% to 100% and intrinsically considers the contribution of donor-related variables such as the pre-procedure mobilization and intra-apheresis recruitment of CD34<sup>+</sup> cells (as a convenient marker for HSCs), as well as the performance of the apheresis system itself.</p>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"39 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2023-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71482000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vascular access for autologous peripheral blood stem cells collection by large volume leukapheresis: Single center experience 通过大容量白血病收集自体外周血干细胞的血管通路:单中心经验。
IF 1.5 4区 医学 Q4 HEMATOLOGY Pub Date : 2023-11-08 DOI: 10.1002/jca.22095
Ines Bojanić MD, PhD, Greta Novosel MSN, Marijana Lukač Baričević MSN, Petar Škrnjug MSN, Elena Horvat BSN, Sanja Mazić MD, PhD, Josip Batinić MD, PhD, Sandra Bašić Kinda MD, PhD, Branka Golubić Ćepulić MD, PhD

Introduction

Peripheral blood stem cell (PBSC) harvesting requires reliable and safe vascular access. In our institution, a change of practice was implemented and the central venous catheter (CVC) placement for all autologous PBSC collections was abandoned in favor of a careful evaluation of peripheral venous access (PVA) for each individual patient. The aim of this prospective study was to evaluate the rate of patients with adequate peripheral veins for autologous PBSC collection and compare patient characteristics, collection efficacy, and complication rate between patients with PVA and CVC.

Method

Peripheral veins were assessed by the apheresis nurse team in all patients referred between January 2020 and July 2021 to autologous PBSC collection. Only in case of difficult venous access, CVC was inserted. Large volume leukapheresis (LVL) procedures, which processed ≥3 total blood volumes, were performed.

Results

In 65 (57%) patients PVA was used, while 49 (43%) patients required placement of short-term CVC. Peripheral venous access was successfully used significantly more often in males (69.8%) (P = 0.010), and patients with multiple myeloma (71.0%) than in patients with non-Hodgkin's lymphoma (35.9%) and Hodgkin's lymphoma patients (33.3%) (P < 0.001). There was a significant difference in the type of prior administered chemotherapy; in the patients who received cytostatics free chemotherapy, PVA was used more often (75.0%) (P = 0.007). In terms of the efficacy and safety of LVLs, there were no differences between procedures performed using PVA and CVCs.

Conclusion

Peripheral venous access is feasible for autologous PBSC collection in more than a half of patients, in particular in those with multiple myeloma. Changes in the treatment of multiple myeloma, using new proteasome inhibitors-based and immunomodulatory agents that do not adversely affect peripheral veins, have enabled the use of PVA even at the high blood flow rates required by LVL. Peripheral venous access is not associated with safety issues or with a lesser collection efficiency, and it is cost-effective as well. Each patient referred to autologous PBSC collection needs to be evaluated individually by the experienced apheresis team for the most appropriate venous access.

简介:外周血干细胞(PBSC)的采集需要可靠和安全的血管通路。在我们的机构中,实施了一项实践变更,放弃了所有自体PBSC采集的中心静脉导管(CVC)放置,转而对每个患者的外周静脉通路(PVA)进行仔细评估。这项前瞻性研究的目的是评估有足够外周静脉进行自体PBSC采集的患者的比率,并比较PVA和CVC患者的患者特征、采集效果和并发症发生率。方法:由单采护士团队对2020年1月至2021年7月期间转诊的所有自体PBSC采集患者的外周静脉进行评估。只有在静脉通路困难的情况下,才插入CVC。进行大容量白血病(LVL)手术,处理≥3个总血容量。结果:65例(57%)患者使用了PVA,49例(43%)患者需要放置短期CVC。男性(69.8%)成功地使用了外周静脉通路(P = 0.010)和多发性骨髓瘤患者(71.0%)高于非霍奇金淋巴瘤(35.9%)和霍奇金淋巴瘤患者(33.3%)(P 结论:对于超过一半的患者,特别是多发性骨髓瘤患者,外周静脉通路用于自体多能干细胞采集是可行的。多发性骨髓瘤治疗的变化,使用新的基于蛋白酶体抑制剂的免疫调节剂,不会对外周静脉产生不利影响,使PVA即使在LVL所需的高血流量下也能使用。外周静脉通路与安全问题或较低的收集效率无关,而且具有成本效益。每一位接受自体PBSC采集的患者都需要由经验丰富的单采团队单独评估,以获得最合适的静脉通路。
{"title":"Vascular access for autologous peripheral blood stem cells collection by large volume leukapheresis: Single center experience","authors":"Ines Bojanić MD, PhD,&nbsp;Greta Novosel MSN,&nbsp;Marijana Lukač Baričević MSN,&nbsp;Petar Škrnjug MSN,&nbsp;Elena Horvat BSN,&nbsp;Sanja Mazić MD, PhD,&nbsp;Josip Batinić MD, PhD,&nbsp;Sandra Bašić Kinda MD, PhD,&nbsp;Branka Golubić Ćepulić MD, PhD","doi":"10.1002/jca.22095","DOIUrl":"10.1002/jca.22095","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Peripheral blood stem cell (PBSC) harvesting requires reliable and safe vascular access. In our institution, a change of practice was implemented and the central venous catheter (CVC) placement for all autologous PBSC collections was abandoned in favor of a careful evaluation of peripheral venous access (PVA) for each individual patient. The aim of this prospective study was to evaluate the rate of patients with adequate peripheral veins for autologous PBSC collection and compare patient characteristics, collection efficacy, and complication rate between patients with PVA and CVC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>Peripheral veins were assessed by the apheresis nurse team in all patients referred between January 2020 and July 2021 to autologous PBSC collection. Only in case of difficult venous access, CVC was inserted. Large volume leukapheresis (LVL) procedures, which processed ≥3 total blood volumes, were performed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In 65 (57%) patients PVA was used, while 49 (43%) patients required placement of short-term CVC. Peripheral venous access was successfully used significantly more often in males (69.8%) <i>(P = 0.010),</i> and patients with multiple myeloma (71.0%) than in patients with non-Hodgkin's lymphoma (35.9%) and Hodgkin's lymphoma patients (33.3%) (<i>P</i> &lt; 0.001). There was a significant difference in the type of prior administered chemotherapy; in the patients who received cytostatics free chemotherapy, PVA was used more often (75.0%) (<i>P</i> = 0.007). In terms of the efficacy and safety of LVLs, there were no differences between procedures performed using PVA and CVCs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Peripheral venous access is feasible for autologous PBSC collection in more than a half of patients, in particular in those with multiple myeloma. Changes in the treatment of multiple myeloma, using new proteasome inhibitors-based and immunomodulatory agents that do not adversely affect peripheral veins, have enabled the use of PVA even at the high blood flow rates required by LVL. Peripheral venous access is not associated with safety issues or with a lesser collection efficiency, and it is cost-effective as well. Each patient referred to autologous PBSC collection needs to be evaluated individually by the experienced apheresis team for the most appropriate venous access.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"39 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2023-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71521611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comorbidity in lipoprotein apheresis: Their role in the era of new lipid-lowering therapies 脂蛋白单采合并症:它们在新的降脂疗法时代的作用。
IF 1.5 4区 医学 Q4 HEMATOLOGY Pub Date : 2023-10-19 DOI: 10.1002/jca.22094
Francesco Sbrana MD, Mascia Pianelli LPN, Roberta Luciani LPN, Federico Bigazzi PhD, Carmen Corciulo PhD, Andrea Ripoli PhD, Tiziana Sampietro MD, Beatrice Dal Pino MD

Background

Despite advance in pharmacotherapy of lipid disorders, lipoprotein apheresis (LA) plays a leading role in the management of severe hypercholesterolemia and in atherosclerosis prevention.

Methods

Aim of this study was to retrospectively evaluate Charlson Comorbidity Index (CCI), presence of major comorbidity, and/or concomitant polypharmacy (definite as 5+ drugs daily) in patients with inherited dyslipidemias on chronic LA.

Results

Since 1994, we performed more than 500 LA treatment/year and followed a total of 83 patients (age 56 [47–65] years, male 75%). In subjects with more than 5 years of LA treatment (38 patients, age 54 [45–62] years, male 66%), at the end of the observation time (9 [7–16] years), patients had higher CCI, polypharmacy, anemia, heart failure, peptic ulcer disease, and benign prostatic hyperplasia.

Discussion

Even in the era of new lipid-lowering therapies, the LA treatment established itself as a safe and lifesaving intervention. Patients on chronic LA require a multidisciplinary approach to address their comorbidity and the apheresis unit's medical staff (doctors and nurses) play a pivotal role creating a bridge toward the general practitioner and other specialists for overcoming clinical issues.

背景:尽管脂质疾病的药物治疗取得了进展,但脂蛋白单采(LA)在治疗严重高胆固醇血症和预防动脉粥样硬化方面发挥着主导作用。方法:本研究的目的是回顾性评估慢性左心房遗传性血脂异常患者的Charlson合并症指数(CCI)、主要合并症的存在和/或伴随的多药治疗(确定为每天5种以上药物)。结果:自1994年以来,我们每年进行500多次左心房治疗,共随访了83名患者(年龄56[47-65]岁,男性75%)。在5岁以上的受试者中 LA治疗年限(38例,年龄54[45-62]岁,男性66%),在观察时间结束时(9[7-16]年),患者有较高的CCI、多药治疗、贫血、心力衰竭、消化性溃疡病和良性前列腺增生。讨论:即使在新的降脂疗法时代,LA治疗也已成为一种安全、挽救生命的干预措施。慢性LA患者需要多学科的方法来解决他们的合并症,单采单位的医务人员(医生和护士)在为全科医生和其他专家克服临床问题搭建桥梁方面发挥着关键作用。
{"title":"Comorbidity in lipoprotein apheresis: Their role in the era of new lipid-lowering therapies","authors":"Francesco Sbrana MD,&nbsp;Mascia Pianelli LPN,&nbsp;Roberta Luciani LPN,&nbsp;Federico Bigazzi PhD,&nbsp;Carmen Corciulo PhD,&nbsp;Andrea Ripoli PhD,&nbsp;Tiziana Sampietro MD,&nbsp;Beatrice Dal Pino MD","doi":"10.1002/jca.22094","DOIUrl":"10.1002/jca.22094","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Despite advance in pharmacotherapy of lipid disorders, lipoprotein apheresis (LA) plays a leading role in the management of severe hypercholesterolemia and in atherosclerosis prevention.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Aim of this study was to retrospectively evaluate Charlson Comorbidity Index (CCI), presence of major comorbidity, and/or concomitant polypharmacy (definite as 5+ drugs daily) in patients with inherited dyslipidemias on chronic LA.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Since 1994, we performed more than 500 LA treatment/year and followed a total of 83 patients (age 56 [47–65] years, male 75%). In subjects with more than 5 years of LA treatment (38 patients, age 54 [45–62] years, male 66%), at the end of the observation time (9 [7–16] years), patients had higher CCI, polypharmacy, anemia, heart failure, peptic ulcer disease, and benign prostatic hyperplasia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion</h3>\u0000 \u0000 <p>Even in the era of new lipid-lowering therapies, the LA treatment established itself as a safe and lifesaving intervention. Patients on chronic LA require a multidisciplinary approach to address their comorbidity and the apheresis unit's medical staff (doctors and nurses) play a pivotal role creating a bridge toward the general practitioner and other specialists for overcoming clinical issues.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"39 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2023-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49677943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic plasma exchange for mechanical red cell hemolysis: A case series 治疗性血浆置换治疗机械性红细胞溶血:病例系列。
IF 1.5 4区 医学 Q4 HEMATOLOGY Pub Date : 2023-10-18 DOI: 10.1002/jca.22093
Chloe E. Douglas, Taylor R. House, Larissa Yalon, Shina Menon

We present three cases of severely elevated plasma free hemoglobin (PFH) in pediatric patients on mechanical circulatory support devices at a tertiary pediatric care center. Due to severe levels of PFH in the setting of critical illness with the inability to pursue immediate mechanical device exchange, membrane filtration therapeutic plasma exchange (TPE) was performed, which resulted in a lowering of PFH levels. However, long-term outcomes were heterogeneous across the cases. This case series reviews patient presentation, organ function before and after TPE, and the overall role of TPE as an effective treatment option to decrease severely elevated PFH levels. In doing so, we hope to add to what is known about the use of TPE for mechanical red cell hemolysis and provide guidance on its use in critically ill patients.

我们报告了三例在三级儿科护理中心使用机械循环支持设备的儿科患者血浆游离血红蛋白(PFH)严重升高的病例。由于在重症情况下PFH水平严重,无法立即进行机械设备交换,因此进行了膜过滤治疗性血浆交换(TPE),导致PFH水平降低。然而,这些病例的长期结果各不相同。本病例系列回顾了患者的表现、TPE前后的器官功能,以及TPE作为降低严重升高的PFH水平的有效治疗选择的总体作用。通过这样做,我们希望增加TPE用于机械性红细胞溶血的已知知识,并为其在危重患者中的使用提供指导。
{"title":"Therapeutic plasma exchange for mechanical red cell hemolysis: A case series","authors":"Chloe E. Douglas,&nbsp;Taylor R. House,&nbsp;Larissa Yalon,&nbsp;Shina Menon","doi":"10.1002/jca.22093","DOIUrl":"10.1002/jca.22093","url":null,"abstract":"<p>We present three cases of severely elevated plasma free hemoglobin (PFH) in pediatric patients on mechanical circulatory support devices at a tertiary pediatric care center. Due to severe levels of PFH in the setting of critical illness with the inability to pursue immediate mechanical device exchange, membrane filtration therapeutic plasma exchange (TPE) was performed, which resulted in a lowering of PFH levels. However, long-term outcomes were heterogeneous across the cases. This case series reviews patient presentation, organ function before and after TPE, and the overall role of TPE as an effective treatment option to decrease severely elevated PFH levels. In doing so, we hope to add to what is known about the use of TPE for mechanical red cell hemolysis and provide guidance on its use in critically ill patients.</p>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"39 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2023-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41235620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hyperchloremic metabolic acidosis after plasma exchange in a patient with renal transplant rejection: A case report 肾移植排斥反应患者血浆置换后的高氯代谢性酸中毒:一例报告。
IF 1.5 4区 医学 Q4 HEMATOLOGY Pub Date : 2023-10-06 DOI: 10.1002/jca.22092
S.S.A. Simon MD, M.S. van Sandwijk MD, PhD, R.H.G. Olde Engberink MD, PhD

Therapeutic plasma exchange (TPE) is an effective treatment for several renal disorders, including renal transplant rejection. However, repeated plasma exchanges can result in various metabolic disturbances and complications. We present a 61-year old male with a medical history of type 2 diabetes, hypertension, successfully treated multiple myeloma, and a post-mortem kidney transplantation 7 months prior to presentation. The patient was hospitalized with an antibody-mediated transplant rejection for which treatment with methylprednisolone, TPE with a 40 g/L albumin solution as a replacement fluid, and intravenous immunoglobulins was initiated. After four TPE treatments, the patient developed gastrointestinal complaints and muscle weakness. Despite daily oral bicarbonate supplementation, laboratory tests revealed a hyperchloremic metabolic acidosis: bicarbonate 11.7 mmol/L, chloride 111 mmol/L, and sodium 138 mmol/L. Metabolic acidosis due to citrate accumulation was ruled out with a normal total-to-ionized calcium ratio. After treatment with intravenous bicarbonate supplementation, the symptoms disappeared. Analysis of the albumin solution showed a chloride concentration of 132 mmol/L. This is the first case that describes severe metabolic acidosis after multiple sessions of TPE with an albumin solution in a patient with impaired renal function. The hyperchloremic metabolic acidosis is the result of administration of large volumes of an albumin solution with high chloride concentrations. Special attention should be paid to the acid–base balance during TPE in patients with impaired renal function. Future research should investigate the incidence of hyperchloremic metabolic acidosis during TPE in patients with impaired renal function.

治疗性血浆置换(TPE)是治疗几种肾脏疾病的有效方法,包括肾移植排斥反应。然而,重复的血浆交换会导致各种代谢紊乱和并发症。我们报告一名61岁男性,有2型糖尿病、高血压病史,成功治疗了多发性骨髓瘤,并进行了尸检肾移植7 演示前几个月。该患者因抗体介导的移植排斥反应而住院,对此,用甲基强的松龙、TPE和40 g/L白蛋白溶液作为置换液,并开始静脉注射免疫球蛋白。经过四次TPE治疗后,患者出现胃肠道不适和肌肉无力。尽管每天口服补充碳酸氢盐,但实验室测试显示存在高氯代谢性酸中毒:碳酸氢盐11.7 mmol/L,氯化物111 mmol/L和钠138 mmol/L。柠檬酸盐积累引起的代谢性酸中毒被排除在总钙与游离钙比例正常的情况下。静脉补充碳酸氢盐治疗后,症状消失。白蛋白溶液的分析显示氯化物浓度为132 mmol/L。这是第一例肾功能受损患者在多次使用白蛋白溶液进行TPE后出现严重代谢性酸中毒的病例。高氯代谢性酸中毒是大量服用高氯浓度白蛋白溶液的结果。肾功能受损患者在TPE过程中应特别注意酸碱平衡。未来的研究应调查肾功能受损患者在TPE期间发生高氯代谢性酸中毒的情况。
{"title":"Hyperchloremic metabolic acidosis after plasma exchange in a patient with renal transplant rejection: A case report","authors":"S.S.A. Simon MD,&nbsp;M.S. van Sandwijk MD, PhD,&nbsp;R.H.G. Olde Engberink MD, PhD","doi":"10.1002/jca.22092","DOIUrl":"10.1002/jca.22092","url":null,"abstract":"<p>Therapeutic plasma exchange (TPE) is an effective treatment for several renal disorders, including renal transplant rejection. However, repeated plasma exchanges can result in various metabolic disturbances and complications. We present a 61-year old male with a medical history of type 2 diabetes, hypertension, successfully treated multiple myeloma, and a post-mortem kidney transplantation 7 months prior to presentation. The patient was hospitalized with an antibody-mediated transplant rejection for which treatment with methylprednisolone, TPE with a 40 g/L albumin solution as a replacement fluid, and intravenous immunoglobulins was initiated. After four TPE treatments, the patient developed gastrointestinal complaints and muscle weakness. Despite daily oral bicarbonate supplementation, laboratory tests revealed a hyperchloremic metabolic acidosis: bicarbonate 11.7 mmol/L, chloride 111 mmol/L, and sodium 138 mmol/L. Metabolic acidosis due to citrate accumulation was ruled out with a normal total-to-ionized calcium ratio. After treatment with intravenous bicarbonate supplementation, the symptoms disappeared. Analysis of the albumin solution showed a chloride concentration of 132 mmol/L. This is the first case that describes severe metabolic acidosis after multiple sessions of TPE with an albumin solution in a patient with impaired renal function. The hyperchloremic metabolic acidosis is the result of administration of large volumes of an albumin solution with high chloride concentrations. Special attention should be paid to the acid–base balance during TPE in patients with impaired renal function. Future research should investigate the incidence of hyperchloremic metabolic acidosis during TPE in patients with impaired renal function.</p>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"39 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2023-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jca.22092","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41162660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adsorptive cytapheresis in ulcerative colitis: A non-pharmacological therapeutic approach revisited 溃疡性结肠炎的吸附性单采:一种非药物治疗方法的再探讨。
IF 1.5 4区 医学 Q4 HEMATOLOGY Pub Date : 2023-10-03 DOI: 10.1002/jca.22091
Filippo Vernia, Angelo Viscido, Giovanni Latella

Adsorptive cytapheresis proves effective in a proportion of patients affected by ulcerative colitis. Relatively high cost and the need for apheresis facilities, prevented the widespread use of this therapeutic approach. More so following the introduction of anti-TNFα biosimilars which proved both effective and inexpensive. Anti-TNFα agents, however, are burdened by high rate of primary and secondary non-response and prompt switching to new, high-cost biologics, and small molecules. The present review analyzes advantages and disadvantages of adsorptive cytapheresis in the present clinical scenario and suggests its repositioning in the therapeutic workup of selected subgroups of ulcerative colitis patients. The extremely favorable safety profile makes adsorptive cytapheresis a viable therapeutic option in elderly and high-risk UC patients, as well as potential second-line treatment in corticosteroid-dependent patients and poor responders to first-line biologics.

吸附性单采被证明对一定比例的溃疡性结肠炎患者有效。相对较高的成本和对单采设施的需求阻碍了这种治疗方法的广泛使用。随着抗TNFα生物类似物的引入,情况更是如此,这些生物类似物被证明既有效又便宜。然而,抗TNFα药物具有高的原发性和继发性无反应率,并迅速转向新的、高成本的生物制剂和小分子。本综述分析了吸附性单采细胞术在当前临床情况下的优缺点,并建议其在溃疡性结肠炎患者的选定亚组的治疗中重新定位。极为有利的安全性使吸附性单采细胞术成为老年和高危UC患者的可行治疗选择,也成为皮质类固醇依赖患者和一线生物制剂反应不佳患者的潜在二线治疗选择。
{"title":"Adsorptive cytapheresis in ulcerative colitis: A non-pharmacological therapeutic approach revisited","authors":"Filippo Vernia,&nbsp;Angelo Viscido,&nbsp;Giovanni Latella","doi":"10.1002/jca.22091","DOIUrl":"10.1002/jca.22091","url":null,"abstract":"<p>Adsorptive cytapheresis proves effective in a proportion of patients affected by ulcerative colitis. Relatively high cost and the need for apheresis facilities, prevented the widespread use of this therapeutic approach. More so following the introduction of anti-TNFα biosimilars which proved both effective and inexpensive. Anti-TNFα agents, however, are burdened by high rate of primary and secondary non-response and prompt switching to new, high-cost biologics, and small molecules. The present review analyzes advantages and disadvantages of adsorptive cytapheresis in the present clinical scenario and suggests its repositioning in the therapeutic workup of selected subgroups of ulcerative colitis patients. The extremely favorable safety profile makes adsorptive cytapheresis a viable therapeutic option in elderly and high-risk UC patients, as well as potential second-line treatment in corticosteroid-dependent patients and poor responders to first-line biologics.</p>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"38 6","pages":"746-754"},"PeriodicalIF":1.5,"publicationDate":"2023-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jca.22091","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41146013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness of leukapheresis on early survival in acute myeloid leukemia: An observational propensity score matching cohort study 白血病治疗对急性髓系白血病早期生存的有效性:一项观察性倾向评分匹配队列研究。
IF 1.5 4区 医学 Q4 HEMATOLOGY Pub Date : 2023-10-03 DOI: 10.1002/jca.22090
Howon Lee, Jay Ho Han, Jae Kwon Kim, Jaeeun Yoo, Hyung Suk Cho, Jae-Ho Yoon, Byung Sik Cho, Hee-Je Kim, Jihyang Lim, Dong Wook Jekarl, Yonggoo Kim

Background

The association between leukapheresis (LK) as a treatment option for hyperleukocytosis (HL) in patients with acute myeloid leukemia (AML) remains controversial.

Methods

Data were extracted from the electronic medical record for 2801 patients with AML between April 2009 and December 2019. LK was performed when the leukocyte count was ≥100 × 109/L at the time initial bone marrow examination.

Results

A comparison between the patients with HL in the non-LK (n = 1579) and LK (n = 208) groups revealed survival probabilities (%) of 93.2% and 90.4% (P = .130) for day 30 (D30), 85.4% and 84.2% (P = .196) for D60, and 83.6% and 80.8% (P = .258) for D90, respectively. After propensity score matching, a comparison between the patients with HL in the non-LK (n = 192) and LK (n = 192) groups revealed survival probabilities (%) of 83.9% and 91.2% (P = .030) for D30, 75.0% and 84.9% (P = .015) for day 60 (D60), and 62.4% and 81.3% (P = .034) for day 90 (D90), respectively. After D150, the observed effect of LK appeared to be mitigated without a survival benefit.

Discussion

LK was associated with improved early survival outcomes at D30, D60, and D90 among patients with AML exhibiting HL. Thus, it may be considered a treatment option for reducing cell mass in such patients.

背景:白血病(LK)作为治疗急性髓系白血病(AML)患者高白细胞增多症(HL)的一种选择之间的关系仍然存在争议。方法:从2009年4月至2019年12月期间2801名AML患者的电子病历中提取数据。当白细胞计数≥100时进行LK × 109/L。结果:非LK(n = 1579)和LK(n = 208)组的生存率分别为93.2%和90.4%(P = .130)、85.4%和84.2%(P = .196)、83.6%和80.8%(P = .258)。在倾向评分匹配后,非LK(n = 192)和LK(n = 192)组的生存率分别为83.9%和91.2%(P = .030)、75.0%和84.9%(P = .015)、62.4%和81.3%(P = .034)分别用于第90天(D90)。D150后,观察到的LK效应似乎减轻了,但没有生存益处。讨论:LK与表现为HL的AML患者在D30、D60和D90时的早期生存结果改善有关。因此,它可以被认为是减少此类患者细胞质量的一种治疗选择。
{"title":"Effectiveness of leukapheresis on early survival in acute myeloid leukemia: An observational propensity score matching cohort study","authors":"Howon Lee,&nbsp;Jay Ho Han,&nbsp;Jae Kwon Kim,&nbsp;Jaeeun Yoo,&nbsp;Hyung Suk Cho,&nbsp;Jae-Ho Yoon,&nbsp;Byung Sik Cho,&nbsp;Hee-Je Kim,&nbsp;Jihyang Lim,&nbsp;Dong Wook Jekarl,&nbsp;Yonggoo Kim","doi":"10.1002/jca.22090","DOIUrl":"10.1002/jca.22090","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The association between leukapheresis (LK) as a treatment option for hyperleukocytosis (HL) in patients with acute myeloid leukemia (AML) remains controversial.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data were extracted from the electronic medical record for 2801 patients with AML between April 2009 and December 2019. LK was performed when the leukocyte count was ≥100 × 10<sup>9</sup>/L at the time initial bone marrow examination.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A comparison between the patients with HL in the non-LK (n = 1579) and LK (n = 208) groups revealed survival probabilities (%) of 93.2% and 90.4% (<i>P</i> = .130) for day 30 (D30), 85.4% and 84.2% (<i>P</i> = .196) for D60, and 83.6% and 80.8% (<i>P</i> = .258) for D90, respectively. After propensity score matching, a comparison between the patients with HL in the non-LK (n = 192) and LK (n = 192) groups revealed survival probabilities (%) of 83.9% and 91.2% (<i>P</i> = .030) for D30, 75.0% and 84.9% (<i>P</i> = .015) for day 60 (D60), and 62.4% and 81.3% (<i>P</i> = .034) for day 90 (D90), respectively. After D150, the observed effect of LK appeared to be mitigated without a survival benefit.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion</h3>\u0000 \u0000 <p>LK was associated with improved early survival outcomes at D30, D60, and D90 among patients with AML exhibiting HL. Thus, it may be considered a treatment option for reducing cell mass in such patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"38 6","pages":"727-737"},"PeriodicalIF":1.5,"publicationDate":"2023-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41115036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Updates on the mobilization pipeline for hematopoietic stem cell collection 造血干细胞采集动员管道的最新情况。
IF 1.5 4区 医学 Q4 HEMATOLOGY Pub Date : 2023-09-25 DOI: 10.1002/jca.22089
Minh-Ha Tran DO, Muharrem Yunce MD

Hematopoetic Stem Cell Transplantation is a life saving procedure which requires mobilization of stem cells for apheresis procedure. In this review we aimed to examine mobilizing agents that are in use and under investigation. Apheresis practitioners who oversee stem cell collections should be familiar with the recent advances in mobilization agents to utilize most up-to-date information for better patient outcomes.

造血干细胞移植是一种挽救生命的手术,需要动员干细胞进行单采手术。在本次审查中,我们旨在审查正在使用和正在调查的动员剂。监督干细胞采集的单采医生应该熟悉动员剂的最新进展,以利用最新信息获得更好的患者结果。
{"title":"Updates on the mobilization pipeline for hematopoietic stem cell collection","authors":"Minh-Ha Tran DO,&nbsp;Muharrem Yunce MD","doi":"10.1002/jca.22089","DOIUrl":"10.1002/jca.22089","url":null,"abstract":"<p>Hematopoetic Stem Cell Transplantation is a life saving procedure which requires mobilization of stem cells for apheresis procedure. In this review we aimed to examine mobilizing agents that are in use and under investigation. Apheresis practitioners who oversee stem cell collections should be familiar with the recent advances in mobilization agents to utilize most up-to-date information for better patient outcomes.</p>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"38 6","pages":"738-745"},"PeriodicalIF":1.5,"publicationDate":"2023-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41127203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Clinical Apheresis
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1